研究者詳細 - 枝園　忠彦

論文 - 枝園　忠彦

分割表示 275 件中 101 - 120 件目／全件表示 >>

ステレオタイプ・スレットという問題とニュースレターの果たす役割

竹原裕子, 溝尾妙子, 小林純子, 坂本美咲, 新田薫, 工藤由里絵, 安井和也, 菊池覚次, 黒田新士, 吉田龍一, 岡崎幹生, 杉本誠一郎, 枝園忠彦, 小谷恭弘, 豊岡伸一, 笠原真悟, 藤原俊義, 土井原博義

日本外科学会定期学術集会抄録集 122回 SP - 6 2022年4月

未来を拓く乳腺外科領域の臨床試験乳癌診療ガイドラインから見た乳がん外科領域の臨床試験

九冨五郎, 坂井威彦, 枝園忠彦, 麻賀創太, 有賀智之, 石飛真人, 久芳さやか, 澤木正孝, 寺田かおり, 冨田興一, 井口雅史, 岩田広治, 佐治重衡

日本外科学会定期学術集会抄録集 122回 WS - 1 2022年4月

未来を拓く乳腺外科領域の臨床試験乳癌診療ガイドラインから見た乳がん外科領域の臨床試験

九冨五郎, 坂井威彦, 枝園忠彦, 麻賀創太, 有賀智之, 石飛真人, 久芳さやか, 澤木正孝, 寺田かおり, 冨田興一, 井口雅史, 岩田広治, 佐治重衡

日本外科学会定期学術集会抄録集 122回 WS - 1 2022年4月

ステレオタイプ・スレットという問題とニュースレターの果たす役割

日本外科学会定期学術集会抄録集 122回 SP - 6 2022年4月

異所性甲状腺腫を疑った頸部正中の低分化がんの一例

中野佳奈子, 奥田静香, 羽原俊宏, 林伸旨, 枝園忠彦, 高橋侑子

乳腺甲状腺超音波医学 11 ( 2 ) 176 - 176 2022年4月

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. 国際誌

Yuichiro Kikawa, Yasuhiro Hagiwara, Tomomi Fujisawa, Kazuhiro Araki, Takayuki Iwamoto, Takafumi Sangai, Tadahiko Shien, Shintaro Takao, Reiki Nishimura, Masato Takahashi, Tatsuya Toyama, Tomohiko Aihara, Hirofumi Mukai, Naruto Taira

PloS one 17 ( 11 ) e0278344 2022年

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: The HORSE-BC study previously demonstrated that second-line endocrine therapy (ET) for patients with acquired endocrine-resistant metastatic breast cancer (MBC) still provided a clinically meaningful benefit. Herein, we investigated the health-related quality of life (HRQOL) in the HORSE-BC study. METHODS: Patients with acquired endocrine-resistant MBC who were scheduled for second-line ET were recruited. The HRQOL was assessed at baseline, and 1 and 3 months after second-line ET initiation. To investigate the minimally important difference (MID) in the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES), we evaluated the means and standard deviations for the distribution-based method, and differences in the change in HRQOL for the anchor-based method. We also investigated the association between FACT-ES total scores and clinical benefit. RESULTS: Overall, 56 patients were enrolled. Of these, 47 were analyzed. When defined as 1/3 standard deviation estimates based on the distribution method, the calculated MID was 5.9. The MIDs of the FACT-ES total scores based on the anchor method were 7.7 for decline and 4.1 for improvement. The MID decline proportions were 6.1% and 14.7% lower in patients who experienced clinical benefits than in those who did not at 1 and 3 months, respectively. The ratios of MID improvement in patients who experienced clinical benefits were 18.3% and 3.2% higher, respectively; the mean change in the FACT-ES total score from baseline improved in patients who experienced clinical benefits. CONCLUSIONS: Maintaining the HRQOL as determined by FACT-ES may be associated with clinical benefits in patients with acquired endocrine-resistant MBC treated with ET.

DOI： 10.1371/journal.pone.0278344

PubMed

researchmap

MEN1疑いの家族歴と上縦隔に進展する副甲状腺癌を認めた1例

大塚勇輝, 長谷川功, 原田洸, 西村義人, 岡浩介, 小野早和子, 枝園忠彦, 平沢晃, 大塚文男

日本内分泌学会雑誌 97 ( 4 ) 946 - 946 2021年12月

MEN1疑いの家族歴と上縦隔に進展する副甲状腺癌を認めた1例

大塚勇輝, 長谷川功, 原田洸, 西村義人, 岡浩介, 小野早和子, 枝園忠彦, 平沢晃, 大塚文男

日本内分泌学会雑誌 97 ( 4 ) 946 - 946 2021年12月

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. 国際誌

Miwa Fujihara, Tadahiko Shien, Kazuhiko Shien, Ken Suzawa, Tatsuaki Takeda, Yidan Zhu, Tomoka Mamori, Yusuke Otani, Ryo Yoshioka, Maya Uno, Yoko Suzuki, Yuko Abe, Minami Hatono, Takahiro Tsukioki, Yuko Takahashi, Mariko Kochi, Takayuki Iwamoto, Naruto Taira, Hiroyoshi Doihara, Shinichi Toyooka

International journal of molecular sciences 22 ( 23 ) 2021年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

Trastuzumab-emtansine (T-DM1) is a therapeutic agent molecularly targeting human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and it is especially effective for MBC with resistance to trastuzumab. Although several reports have described T-DM1 resistance, few have examined the mechanism underlying T-DM1 resistance after the development of acquired resistance to trastuzumab. We previously reported that YES1, a member of the Src family, plays an important role in acquired resistance to trastuzumab in HER2-amplified breast cancer cells. We newly established a trastuzumab/T-DM1-dual-resistant cell line and analyzed the resistance mechanisms in this cell line. At first, the T-DM1 effectively inhibited the YES1-amplified trastuzumab-resistant cell line, but resistance to T-DM1 gradually developed. YES1 amplification was further enhanced after acquired resistance to T-DM1 became apparent, and the knockdown of the YES1 or the administration of the Src inhibitor dasatinib restored sensitivity to T-DM1. Our results indicate that YES1 is also strongly associated with T-DM1 resistance after the development of acquired resistance to trastuzumab, and the continuous inhibition of YES1 is important for overcoming resistance to T-DM1.

DOI： 10.3390/ijms222312809

PubMed

researchmap

岡山大学外科広域外科専門研修プログラム関連病院における専攻医の産前産後休暇・育児休業/休暇・介護休業/休暇、その他支援についての実態調査

竹原裕子, 溝尾妙子, 小林純子, 菊地覚次, 池田宏国, 岡崎幹生, 吉田龍一, 黒田新士, 枝園忠彦, 小谷恭弘, 山根正修, 豊岡伸一, 笠原真悟, 土井原博義, 藤原俊義

日本臨床外科学会雑誌 82 ( 増刊 ) S24 - S24 2021年10月

岡山大学外科広域外科専門研修プログラム関連病院における専攻医の産前産後休暇・育児休業/休暇・介護休業/休暇、その他支援についての実態調査

日本臨床外科学会雑誌 82 ( 増刊 ) S24 - S24 2021年10月

長期にわたって乳房腫瘤を自覚していた若年乳癌の一例

中川里沙子, 宇野摩耶, 岩本高行, 三又明日香, 間森智加, 安部優子, 鳩野みなみ, 西村碧フィリーズ, 高橋侑子, 河内麻里子, 都地友紘, 枝園忠彦, 平成人, 柳井広之, 土井原博義

日本臨床外科学会雑誌 82 ( 増刊 ) S1220 - S1220 2021年10月

乳がん治療における手術省略の可能性乳がん非切除療法の検証特定臨床研究JCOG1806の挑戦

藤澤知巳, 重松英朗, 枝園忠彦, 石塚俊之, 田中希世, 木川雄一郎, 鹿間直人, 吉村通央, 岩田広治, 佐々木啓太

日本臨床外科学会雑誌 82 ( 増刊 ) S123 - S123 2021年10月

乳癌治療におけるデエスカレーションとエスカレーション-さらなる個別化- HER2陽性乳癌に対する根治的化学療法+放射線療法の可能性

重松英朗, 藤澤知巳, 枝園忠彦, 田中希世, 石場俊之, 椋本宜学, 吉村通央, 鹿間直人, 岩田広治

日本癌治療学会学術集会抄録集 59回 SY3 - 2 2021年10月

A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). 国際誌

Akihiko Shimomura, Kenji Tamura, Kiyo Tanaka, Tomonori Mizutani, Keita Sasaki, Yuta Sekino, Masataka Sawaki, Tadahiko Shien, Taro Shibata, Hiroji Iwata

Japanese journal of clinical oncology 51 ( 9 ) 1471 - 1474 2021年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

The standard first-line treatment for patients with human epidermal growth factor 2-positive metastatic breast cancer is a combination therapy of trastuzumab, pertuzumab and docetaxel, and the standard second-line treatment is trastuzumab emtansine. However, it may be difficult for the elderly to maintain sufficient intensity of treatment due to severe adverse events of trastuzumab, pertuzumab and docetaxel. The aim of this trial is to confirm the non-inferiority of trastuzumab emtansine over trastuzumab, pertuzumab and docetaxel in terms of overall survival in elderly (65-year-old or more) patients with human epidermal growth factor 2-positive metastatic breast cancer. If improved overall survival and fewer toxicities are observed, trastuzumab emtansine may be a feasible new standard first-line treatment for elderly patients with human epidermal growth factor 2-positive metastatic breast cancer. A planned total 330 patients will be enrolled from 45 institutions over 6.5 years. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000030783 [http://www.umin.ac.jp/ctr/index.htm].

DOI： 10.1093/jjco/hyab101

PubMed

researchmap

Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). 国際誌

Akihiko Shimomura, Kenji Tamura, Kiyo Tanaka, Tomonori Mizutani, Keita Sasaki, Yuta Sekino, Masataka Sawaki, Tadahiko Shien, Taro Shibata, Hiroji Iwata

Japanese journal of clinical oncology 51 ( 9 ) 1479 - 1479 2021年8月

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.

Kiyo Tanaka, Norikazu Masuda, Naoki Hayashi, Yasuaki Sagara, Fumikata Hara, Takayuki Kadoya, Akira Matsui, Chieko Miyazaki, Tadahiko Shien, Eriko Tokunaga, Takako Hayashi, Naoki Niikura, Shigeto Maeda, Yoshihumi Komoike, Hiroko Bando, Chizuko Kanbayashi, Hiroji Iwata

Breast cancer (Tokyo, Japan) 28 ( 4 ) 896 - 903 2021年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: We conducted a prospective study with the intention to omit surgery for patients with ductal carcinoma in situ (DCIS) of the breast. We aimed to identify clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with DCIS. PATIENTS AND METHODS: We retrospectively analyzed patients with DCIS diagnosed through biopsy between April 1, 2010 and December 31, 2014, from 16 institutions. Clinical, radiological, and histological variables were collected from medical records. RESULTS: We identified 2,293 patients diagnosed with DCIS through biopsy, including 1,663 DCIS (72.5%) cases and 630 IDC (27.5%) cases. In multivariate analysis, the presence of a palpable mass (odds ratio [OR] 1.8; 95% confidence interval [CI] 1.2-2.6), mammography findings (≥ category 4; OR 1.8; 95% CI 1.2-2.6), mass formations on ultrasonography (OR 1.8; 95% CI 1.2-2.5), and tumor size on MRI (> 20 mm; OR 1.7; 95% CI 1.2-2.4) were independent predictors of IDC. Among patients with a tumor size on MRI of ≤ 20 mm, the possibility of postoperative upstaging to IDC was 22.1%. Among the 258 patients with non-palpable mass, nuclear grade 1/2, and positive for estrogen receptor, the possibility was 18.1%, even if the upper limit of the tumor size on MRI was raised to ≤ 40 mm. CONCLUSION: We identified four independent predictive factors of upstaging to IDC after surgery among patients with DCIS diagnosed by biopsy. The combined use of various predictors of IDC reduces the possibility of postoperative upstaging to IDC, even if the tumor size on MRI is larger than 20 mm.

DOI： 10.1007/s12282-021-01225-0

PubMed

researchmap

Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.

Masafumi Inokuchi, Goro Kutomi, Yuko Kijima, Takehiko Sakai, Masataka Sawaki, Tadahiko Shien, Noriko Hanamura, Kenji Yano, Noriaki Wada, Shigehira Saji, Hiroji Iwata

Breast cancer (Tokyo, Japan) 28 ( 4 ) 989 - 989 2021年7月

乳癌肺oligometastasisの診断・治療の現状と予後の前向き検討

前田礼奈, 枝園忠彦, 高橋三奈, 河田健吾, 梶原友紀子, 久保慎一郎, 高畠大典, 大谷彰一郎, 松岡欣也, 曳野肇, 小笠原豊, 平成人, 大住省三, 池田雅彦, 土井原博義

日本乳癌学会総会プログラム抄録集 29回 62 - 62 2021年7月

術後卵巣癌の診断となったBRCA変異陽性乳癌の2例

藤原由樹, 枝園忠彦, 前田礼奈, 間森智加, 大谷悠介, 吉岡遼, 鳩野みなみ, 笹原麻子, 梶原友紀子, 河内麻里子, 岩本高行, 平成人, 土井原博義

日本乳癌学会総会プログラム抄録集 29回 52 - 52 2021年7月

　前のページ - 次のページ　

<枝園 忠彦>

論文 - 枝園 忠彦

<枝園　忠彦>

論文 - 枝園　忠彦